The role of cereblon (CRBN) in T cells is not well understood. We generated mice with a deletion in Crbn and found cereblon to be an important antagonist of T-cell activation. In mice lacking CRBN, CD4
+ T cells show increased activation and IL-2 production on T-cell receptor stimulation, ultimately resulting in increased potassium flux and calcium-mediated signaling. CRBN restricts T-cell activation via epigenetic modification of Kcna3, which encodes the Kv1.3 potassium channel required for robust calcium influx in T cells. CRBN binds directly to conserved DNA elements adjacent to Kcna3 via a previously uncharacterized DNA-binding motif. Consequently, in the absence of CRBN, the expression of Kv1.3 is derepressed, resulting in increased Kv1.3 expression, potassium flux, and CD4 + T-cell hyperactivation. In addition, experimental autoimmune encephalomyelitis in T-cell-specific Crbn-deficient mice was exacerbated by increased T-cell activation via Kv1.3. Thus, CRBN limits CD4 + T-cell activation via epigenetic regulation of Kv1.3 expression.
T-cell activation | CRBN | Kv1.3 | calcium flux | potassium flux R ecent studies have identified cereblon (CRBN) as a thalidomidebinding protein (1, 2) . CRBN is expressed in the cytoplasm, nucleus, and peripheral membranes of a wide variety of cells and tissues (1, (3) (4) (5) . CRBN forms an E3 ubiquitin ligase complex with damaged DNA-binding protein (DDB) 1 and Cul4A, and this complex is involved in limb outgrowth and controls fibroblast growth factor 8 expression in zebrafish and chicks (1) . When thalidomide binds to CRBN, it inhibits formation of the E3 ubiquitin ligase complex, which in turn reduces the activity of the ubiquitin ligase and results in defective limb development (1) .
Recent work suggests that immunomodulatory drugs (IMiDs) stimulate increased IL-2 production in T cells by binding to CRBN. This binding alters the substrate specificity of CRBN-containing ubiquitin ligase complexes (6, 7) even though IMiDs reduce the overall activity of E3 ubiquitin ligase (1) . As a result, binding promotes abnormal degradation of the Ikaros zinc finger proteins 1 and 3 (IKZF1 and IKZF3), which in turn increases IL-2 production in T cells (6) (7) (8) . However, although the CRBN-mediated effects of IMiDs are known, the physiological role of CRBN in T cells remains unclear.
We deleted the Crbn gene from murine T cells to examine the physiological role of CRBN during T-cell activation, with the aim of gaining new insight into the regulation of potassium flux during T-cell signaling. Deletion of Crbn from T cells led to IL-2 production and differentiation of CD4 + T cells into Th17 effector cells, as well as worsening of the phenotype associated with experimental autoimmune encephalitis (EAE). CRBN represses T-cell activation by binding to the chromosomal regions adjacent to the Kcna3 locus, a gene encoding the Kv1.3 potassium channel, which participates in calcium influx in T cells. The binding of CRBN to Kcna3 leads to epigenetic modification of the Kcna3 locus and reduces the expression of Kv1.3. Triggering of TCR signaling in CRBN-deficient T cells results in (i) increased potassium and calcium flux, (ii) increased activation of transcription factor NF-AT, and (iii) increased production of IL-2. Our data identify CRBN as an important regulator of T-cell activation, restricting calcium influx via epigenetic repression of Kcna3.
Results

CRBN Deficiency Does Not Affect T-Cell Development, but Does
Increase T-Cell Activation. Analysis of the relative levels of CRBN transcripts in multiple tissue types using the Novartis BioGPS expression array database (biogps.org) (9) suggested that the expression of CRBN mRNA is higher in lymphoid cells, including CD4
+ T cells, than in other cell types (Fig. S1A) . Thus, we used Crbn gene-targeted mice to examine the effect of CRBN deficiency in T-cell development and activation. First, we confirmed the loss of CRBN protein from CD4 + T cells isolated from Crbndeficient (Crbn −/− ) mice (Fig. 1A ). There were no obvious changes in thymic T-cell development (Fig. 1B) . In addition, peripheral T-cell and B-cell populations in 6-to 8-wk-old Crbn −/− mice were no different from those in 6-to 8-wk-old littermate control (Crbn +/− ) mice ( Fig. 1 C and D and Fig. S2A) 1E) . In contrast to T cells, on B cells a loss of CRBN did not affect the activation-induced cell surface expression of CD69 and CD86 (Fig. S2C) .
Along with the expression of activation markers on the cell surface, anti-CD3-and anti-CD28-stimulated CD4 + Tn and Tem cells from CRBN-deficient mice were more proliferative (Fig. 1F ) and secreted higher levels of IL-2 compared with CD4 + Tn and Tem cells, respectively, from their littermate control mice (Fig. 1G ) and showed increased transcription of IL-2 mRNA (Fig.  1H) . Moreover, stimulation with phorbol 12-myristate 13-acetate (PMA) and ionomycin, which bypasses TCR-and CD28-mediated proximal signaling events, still led to increased IL-2 secretion and increased IL-2 mRNA levels in CRBN-deficient CD4 + Tn and Tem cells ( Fig. 1 I and J) . Consistent with these data, CRBN overexpression significantly reduced activation-induced expression of cell surface markers, such as CD69 and CD25, and IL-2 production in Jurkat T cells (Fig. S3 A and B) and in mouse CD4 + T cells ( Fig. S3 C and D) . The increased IL-2 production was not caused by alterations in IKZF1 and IKZF3 protein levels, because CRBN deficiency did not affect these proteins in CD4 + Tn and Tem cells (Fig. S4) . (Fig. 2A) . The NF-κB pathway in CD4 + T cells also was unaffected, because IκBα degradation ( Fig. 2A) and NF-κB DNA-binding activity (Fig. 2B) were unchanged in CRBNdeficient CD4
+ Tn and Tem cells. However, we found it interesting that NF-AT DNA binding ( Fig. 2 B and C) and nuclear localization ( Fig. 2D ) in CRBN-deficient CD4 + Tn and Tem cells were increased after activation, suggesting that loss of CRBN in CD4 + T cells affects primarily the NF-AT activation signaling pathway.
To identify the genes responsible for the increased activation of NF-AT observed in CRBN-deficient CD4 + T cells, we examined gene expression patterns in CD4 + Tn cells from CRBNdeficient mice and their normal littermates. We identified 674 down-regulated genes and 263 up-regulated genes in CRBNdeficient CD4
+ Tn cells (Fig. S5A ). When these differentially expressed genes were categorized, we found that genes related to TCR signaling were affected in the absence of CRBN (Fig. S5B ). Of these TCR signaling-related genes, Zap70 and Kcna3 showed the greatest differences in CRBN-deficient CD4 + Tn cells (Fig. 2E ). Although Zap70 is involved in most TCR signaling pathways, only NF-AT was specifically affected by CRBN deficiency. Thus, we narrowed our focus to Kv1.3, because this channel protein is involved in potassium flux, which is linked to calcium flux.
Consistent with increased NF-AT activation, CD4 + Tn and Tem cells from Crbn −/− mice also had increased calcium flux compared with CD4 + Tn and Tem cells from Crbn +/− mice ( Fig.  2F ). This finding suggests that in the absence of CRBN, increased TCR-induced CD4 + T-cell activation results from increased calcium flux and the subsequent increase of NF-AT activation (Fig. 2G) . In Tem cells, the voltage-dependent Kv1.3 channel is essential for optimal calcium flux during TCR stimulation, because these cells express more Kv1.3 compared with Tn cells (10) . In addition, calcium flux was reduced in CRBN-deficient CD4 + Tn cells when Shk-Dap22, a specific inhibitor of Kv1.3 (11), was added, whereas calcium flux in control CD4 + Tn cells was barely affected (Fig. 2F) + Tn and Tem cells, was reduced by Shk-Dap22 in a manner similar to that observed with calcium flux (Fig. 2G) .
To determine whether Kv1.3 function was also affected, we measured potassium mobilization directly. Potassium flux was also greater in CRBN-deficient CD4 + Tn and Tem cells compared with the littermate control CD4 + Tn and Tem cells and, similar to what we observed with calcium flux, this increase in potassium mobilization was reduced when Shk-Dap22 was added (Fig. 2H) (Fig. 2J) .
CRBN Controls Histone Modification of Kcna3 Regulatory Regions in CD4
+ T Cells. Recent studies have shown that Cul4A, which binds to CRBN, plays a role in histone modification (12) (13) (14) (15) . Moreover, analysis of the relative levels of Cul4A transcripts in multiple tissue types using the Novartis BioGPS expression array database (9) revealed that, like CRBN, Cul4A is expressed to the greatest extent in lymphoid cells (including CD4 + T cells) compared with other cell types (Fig. S1B ). This led us to investigate whether CRBN is an epigenetic regulator of the Kcna3 gene, which encodes Kv1.3. To investigate this possibility, we used chromatin immunoprecipitation (ChIP) analysis to measure the trimethylation of lysine 27 on histone H3 (H3K27me3), which inhibits gene transcription, and the acetylation of lysine 27 on histone H3 (H3K27ac), which activates gene transcription. In the Kcna3 region of CD4 + T cells from Crbn +/− and Crbn −/− mice, we analyzed the status of H3K27 modification at five selected regions, including one 5′ upstream region (R1), two ORF regions (R2 and R3), and two 3′ downstream regions (R4 and R5), on Kcna3 itself (Fig. 3A) . In addition, we verified that CRBN is recruited to Kcna3 (Fig. 3A) , because CRBN regulates the expression of Kv1.3 mRNA (Fig. 2 I and J) . Our results indicate that the CRBN protein is enriched at the R4 region, which is a 3′ downstream conserved region of Kcna3 (Fig. 3A) . Interestingly, CRBN deficiency altered the modification of H3K27 in the R4 region of CD4 + T cells (Fig. 3A) . At regions inside the Kcna3 ORF, including the R3 region, loss of CRBN significantly reduced H3K27me3 levels, whereas H3K27ac levels increased significantly (Fig. 3A) . Reporter gene analysis revealed that the R4 region can enhance the Kcna3 promoter (Fig. 3B) .
Finally, we performed immunoblot analysis with H3K27ac-and H3K27me3-specific antibodies to determine whether CRBN alters global H3K27 modification. We found no global changes in H3K27 modification in CRBN-deficient CD4 + T cells (Fig.  3C) , suggesting that CRBN does not regulate the global pattern of histone modifications in CD4 + T cells, similar to what has been reported about the regulation of histone modification by MSI4/FVE (12) .
Because H3K27 methylation is mediated by EZH1 or EZH2, we attempted to identify the histone methyltransferase responsible for modifying H3K27me3 at Kcna3. We first examined the binding of CRBN to EZH1 or EZH2 in nuclear fractions, and found that CRBN bound to Cul4A, DDB1, and EZH1, but only weakly to EZH2 (Fig. 3D) . In addition, ChIP analysis showed that Cul4A (Fig. 3E) and DDB1 (Fig. 3F) were recruited to Kcna3 in CD4 + T cells; however, the loss of CRBN adversely affected recruitment of Cul4A (Fig. 3E) and DDB1 (Fig. 3F ). In addition, EZH1 was more enriched than EZH2 at the R4 region; however, EZH1 recruitment to Kcna3 was markedly reduced when CRBN was absent (Fig. 3G) . Consistent with these results, down-regulation of EZH1 and Cul4A in CD4 + T cells increased Kv1.3 mRNA levels (Fig. S6) . In addition, the half-life of the Kv1.3 protein was not altered by CRBN overexpression (Fig. S7 ).
The C-Terminal Domain of CRBN Is Crucial for CRBN Enrichment on
Kcna3 Chromatin. Analysis of the CRBN amino acid sequence using the Pfam domain library revealed the presence of the LON motif and Yippee, a novel DNA-binding motif (Fig. 4A) . Moreover, the DNA-binding motif of CRBN is situated in an area in which substrates generally bind to WD40 DDB1/CUL4-associated factors, such as DDB2, to engage DNA (16) . Therefore, we tested whether this potential DNA-binding motif of CRBN is required for binding to the Kcna3 R4 region. In Jurkat T cells, deleting the Yippee-Mis18 motif from CRBN abolished its ability to bind Kcna3 chromatin (Fig. 4A) . In addition, to test whether CRBN can directly bind to Kcna3 DNA, we expressed maltose-binding protein (MBP)-tagged full-length CRBN, the N terminus of CRBN, and the C terminus of CRBN in E. coli and purified the proteins. The purity of the proteins, as assessed by SDS/PAGE and Coomassie blue staining, was >90% (Fig. 4B) . The purified proteins were readily detected by immunoblot analysis with anti-MBP antibodies (Fig. 4B ). Using these recombinant CRBN constructs, we determined whether CRBN binds directly to the R4 region of Kcna3 DNA. Full-length CRBN and the C-terminal CRBN fragment containing the Yippee-Mis18 motif, but not the N-terminal region, was able to bind to the Kcna3 DNA (Fig. 4C) . Therefore, CRBN directly binds to the Kcna3 regulatory region R4 via the C-terminal Yippee-Mis18 motif (Fig. 4C) . The thalidomide-binding region in CRBN is located within the C terminus of CRBN and is essential for CRBN binding to Kcna3 DNA; therefore, we hypothesized that thalidomide prevents CRBN from binding to Kcna3. Consistent with this hypothesis, we found that long-term thalidomide treatment (>6 h) increased activation-induced Kv1.3 expression in CD4 + T cells (Fig. 4D ) and reduced recruitment of CRBN to Kcna3 R4 (Fig. 4E) . Previous reports have shown that thalidomide affects histone modifications (17, 18) , and our present results demonstrate that thalidomide alters the epigenetic modifications of the Kcna3 locus specifically (Fig. 4 F 
and G).
Crbn Deficiency Exacerbates EAE. T-cell activation is important for disease progression in the mouse model for EAE, and the Th17 cell population is particularly important. In addition, NF-AT is important for Th17 cell differentiation. We found that CD4 + T cells lacking CRBN have a greater potential for differentiation into Th17 cells in vitro (Fig. 5A ). Thus, we tested the susceptibility of Crbn-deficient mice for developing EAE, which is mediated by Th17 cells. We used T-cell-specific Crbn-deficient (Crbn flox/flox ;Cd4-Cre) mice, because CRBN deficiency can affect the activity of other immune cells even though CRBN is preferentially expressed in T cells. In addition, T-cell-specific Crbn deficiency does not affect thymic T-cell development (Fig. S8A) , nor does it alter the peripheral T-cell and B-cell populations in the littermate control (Crbn +/flox ;Cd4-Cre) mice (Fig. S8 B and  C) . The absence of CRBN protein expression in CD4 + T cells from Crbn flox/flox ;Cd4-Cre mice was confirmed by immunoblot analysis (Fig. S8D) . In addition, surface expression of activation markers, such as CD69 and CD25 (Fig. S8E) , and IL-2 production (Fig. S8 F-I (Fig. 5D) . The percentages of Th17 and Th1 cells in the periphery and spinal cord of immunized mice were significantly higher in Crbn flox/flox ;Cd4-Cre mice than in Crbn +/flox ;Cd4-Cre mice (Fig. 5  E and F) . In addition, the population of GM-CSF-producing CD4 + T cells was also higher in the spinal cords of Crbn flox/flox ; Cd4-Cre mice than in the spinal cords of Crbn +/flox ;Cd4-Cre mice (Fig. 5F ). Moreover, T-cell-specific deletion of Crbn also increased the production of IL-17A and IFN-γ cytokines by peripheral MOG 35-55 -specific T cells after MOG 35-55 immunization and recall stimulation ex vivo (Fig. 5G ). In addition, the EAE symptoms were reduced by the Kv1.3-specific inhibitor Shk-Dap22, and worsening of the EAE symptoms in Crbn flox/flox ;Cd4-Cre mice was halted to levels seen in the EAE-induced Crbn +/flox ;Cd4-Cre mice treated with Shk-Dap22 (Fig. 5 H and I) . Crbn −/− mice exhibited effects similar to those seen in Crbn flox/flox ;Cd4-Cre mice for in vitro Th17 cell differentiation (Fig. S9) and the EAE mouse model (Fig. S10) . Thus, CRBN is an important antagonist of T-cell activation and limits disease pathogenesis in a mouse model for T-cell-mediated autoimmunity. (12, 15) . We found that CRBN is responsible for EZH1 (a histone methyltransferase for H3K27 modification) recruitment to Kcna3 chromatin. Finally, increased expression of Kv1.3 in T cells lacking CRBN results in increased potassium flux and, subsequently, increased calcium flux, T-cell activation, and IL-2 production in vitro. These changes were associated with increased susceptibility to T-cell-mediated autoimmunity in vivo. These observations are consistent with reports showing that Kv1.3 blockade reduces both T-cell activation and the susceptibility of mice to T-cell-mediated autoimmune disorders, such as EAE (19, 20) . This suggests that CRBN acts as an important controller of calcium influx in T cells by regulating Kcna3 expression. In addition, prolonged treatment of T cells with thalidomide can affect the expression of Kv1.3 by regulating histone modifications in Kcna3, because the thalidomide-binding region in CRBN is located within a newly identified DNA-binding domain. We found that thalidomide treatment blocks recruitment of CRBN to the Kcna3 locus and affects histone modifications (i.e., H3K27me3 was decreased and H3K27Ac was increased). Interestingly, however, whereas previous reports showed that specific enhancement of calcium signaling ameliorates EAE symptoms (21, 22) , our data show that Crbn −/− mice and Crbn flox/flox ; Cd4-Cre mice display exacerbated and sustained EAE symptoms even though potassium flux-coupled calcium flux is increased in the Crbn-deficient CD4 + T cells. Other reports have shown that thalidomide treatment relieves EAE symptoms (23) whereas CRBN deficiency increases these symptoms. Apparently, CRBN is capable of "off-target" degradation activity in the presence of IMiDs. Thus, although thalidomide inhibits the DNA-binding ability of CRBN, IMiDs can affect other CRBN functions, such as off-target degradation, which possibly results from differences in CRBN deficiency and thalidomide treatment in the EAE mouse model. Other unidentified targets of IMiDs can also affect these results. Therefore, it is possible that increasing the potassium flux-coupled calcium flux in the Crbn-deficient CD4 + T cells creates a different intracellular environment compared with increasing calcium flux only, because cytosolic calcium levels are increased by decreasing the cytosolic potassium concentration during T-cell activation. In addition, unidentified downstream signaling cascade differences between CRBN and other calcium-signaling regulators, such as Golli, may possibly contribute to the aforementioned differences in the EAE mouse model.
In conclusion, our results demonstrate that CRBN plays an important role during T-cell activation. CRBN restricts potassium flux by directly modulating the histone modification of Kcna3 chromatin, thereby inhibiting the expression of Kv1.3. Finally, the difference in expression of CRBN in T cells could serve to regulate sensitivity to TCR stimulation.
Materials and Methods
Information on mice, cells, antibodies, plasmids, flow cytometry analysis, the nuclear complex coimmunoprecipitation (co-IP) assay, the microarray analysis, quantitative RT-PCR, calcium and potassium flux, ChIP, Kcna3 sequence analysis, the Kcna3 gene luciferase assay, measurement of NF-AT-and NF-κB-specific DNA-binding activity, the EAE model, the proliferation assay, and cytokine measurement is provided in SI Materials and Methods. All animal experiments were approved by the Gwangju Institute of Science and Technology's Institutional Animal Care and Use Committee.
